NVL-655A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Sponsor:

Nuvalent Inc.

Code:

NCT05384626

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Neladalkib (NVL-655)

Midazolam

Repaglinide

Itraconazole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-01. This information was provided to ClinicalTrials.gov by Nuvalent Inc. on 2026-05-27.